Rekombinanter Tumor Suppressor ARF (CDKN2A) (full length) Antikörper

Produktnummer ABIN7879269

Der Kaninchen Monoklonal anti-Tumor Suppressor ARF Antikörper wird verwendet zum Nachweis von Tumor Suppressor ARF in Proben von Human. Er wurde validiert für IHC (p).

Kurzübersicht für Rekombinanter Tumor Suppressor ARF (CDKN2A) (full length) Antikörper (ABIN7879269)

Target: Tumor Suppressor ARF (CDKN2A)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Monoklonal

Konjugat: Unkonjugiert

Applikation: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Klon: CDKN2A-8196R

Produktdetails

Bindungsspezifität: full length

Verwendungszweck: P16INK4a Antibody / Cyclin-dependent kinase inhibitor 2A Antibody / CDKN2A

Aufreinigung: Protein A/G affinity

Immunogen: Purified recombinant prokaryotic full-length human protein was used as the immunogen for the P16INK4a antibody.

Isotyp: IgG, kappa

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the P16INK4a antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Aliquot the P16INK4a antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Antigendetails

Target: Tumor Suppressor ARF (CDKN2A)

Andere Bezeichnung: P16INK4a / Cyclin-dependent kinase inhibitor 2A

Hintergrund: P16INK4a is a tumor suppressor protein. It is a specific inhibitor of cdk4/cdk6, and a tumor suppressor involved in the pathogenesis of a variety of malignancies. Recent analyses of the p16INK4a gene revealed homozygous deletions, nonsense, missense, or frameshift mutations in several human cancers. Although the frequency of p16INK4a abnormalities is higher in tumor derived cell lines than in unselected primary tumors, significant subsets of clinical cases with aberrant p16INK4a gene have been reported among melanomas, gliomas, esophageal, pancreatic, lung, and urinary bladder carcinomas, and some types of leukemia. Expression of p16INK4a (p16 positive) is highly correlated with human papilloma virus (HPV) infection in head and neck squamous cell carcinomas (HNSCC). p16 status is an important prognostic indicator in HNSCC and the p16 positive/HPV16 negative group is likely a distinct subgroup lacking any HPV genotype.

UniProt: P42771